Literature DB >> 11168932

Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.

M Islam1, J F Burke, T A McGowan, Y Zhu, S R Dunn, P McCue, J Kanalas, K Sharma.   

Abstract

BACKGROUND: Several experimental and clinical studies have implicated a role for transforming growth factor-beta (TGF-beta) in mediating the nephrotoxic effects of cyclosporine (CsA). To test this hypothesis, we administered neutralizing anti-TGF-beta antibodies (alpha-TGF-beta) in a well-described rat model of chronic CsA nephrotoxicity.
METHODS: We studied three groups (N = 9 per group) of adult, male Sprague-Dawley rats that received a low-salt diet (0.05% sodium). Normal controls were given vehicle subcutaneously and an alternate-day intraperitoneal injection of 3 mg of nonspecific mouse IgG (MIgG) for 28 days. The CsA group received 15 mg/kg/day of CsA subcutaneously and 3 mg of MIgG intraperitoneally on alternate days for 28 days. The CsA/alpha-TGF-beta group received CsA and alternate-day alpha-TGF-beta (3 mg) for 28 days. At the end of 28 days, creatinine clearance was measured by 24-hour urine collection. Histologic assessment was performed for tubulointerstitial damage and arteriolar hyalinosis. Northern analysis was performed for alpha 1(I) collagen and TGF-beta 1 gene expression, and quantitative reverse transcription-polymerase chain reaction was performed to measure levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinase-2 (MMP-2), and MMP-9.
RESULTS: CsA-treated rats had significantly lower creatinine clearance as compared with normal controls (0.43 +/- 0.07 vs. 0.67 +/- 0.14 mL/min, P = 0.0002), increased interstitial damage and afferent arteriolar hyalinosis (P = 0.0001), and increased alpha1(I) collagen (4-fold) and TGF-beta 1 (2.5-fold) mRNA expression. CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P < 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P < 0.02) and decreased MMP-9 (85% reduction, P < 0.001) as compared with controls. Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P < 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.
CONCLUSIONS: In this rat model of CsA-induced nephrotoxicity, renal insufficiency and characteristic histologic changes are associated with altered expression of matrix and matrix-regulating molecules. Based on our results with alpha-TGF-beta antibodies, many but not all of these nephrotoxic effects of CsA are mediated by TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168932     DOI: 10.1046/j.1523-1755.2001.059002498.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Cyclosporine A treatment in patients with Alport syndrome: a single-center experience.

Authors:  Laura Massella; Andrea Onetti Muda; Antonia Legato; Giacomo Di Zazzo; Kostas Giannakakis; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

2.  NFATc is required for TGFbeta-mediated transcriptional regulation of fibronectin.

Authors:  Scott L Cobbs; Jennifer L Gooch
Journal:  Biochem Biophys Res Commun       Date:  2007-08-13       Impact factor: 3.575

3.  Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats.

Authors:  Atsushi Yamauchi; Ryozo Oishi; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-10       Impact factor: 5.046

4.  Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage.

Authors:  Vijay Saxena; Douglas W Lienesch; Min Zhou; Ramireddy Bommireddy; Mohamad Azhar; Thomas Doetschman; Ram Raj Singh
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

5.  Pirfenidone is renoprotective in diabetic kidney disease.

Authors:  Satish P RamachandraRao; Yanqing Zhu; Timothy Ravasi; Tracy A McGowan; Irene Toh; Stephen R Dunn; Shinichi Okada; Michael A Shaw; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 10.121

Review 6.  The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis.

Authors:  Sungchun Lee; Sohee Lee; Kumar Sharma
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

7.  Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury.

Authors:  Sun W Lim; Long Jin; Shang G Piao; Byung H Chung; Chul W Yang
Journal:  Lab Invest       Date:  2015-08-03       Impact factor: 5.662

8.  Endothelial cell transforming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis.

Authors:  Valorie L Chiasson; Kathleen A Jones; Shelley E Kopriva; Ashutosh Mahajan; Kristina J Young; Brett M Mitchell
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

9.  Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction.

Authors:  Jianping Dai; Stéphanie Michineau; Grégory Franck; Pascal Desgranges; Jean-Pierre Becquemin; Marianne Gervais; Eric Allaire
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

10.  Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation.

Authors:  Fei Zhao; ShiJiang Zhang; YiJiang Chen; WeiDong Gu; BuQing Ni; YongFeng Shao; YanHu Wu; JianWei Qin
Journal:  BMC Cardiovasc Disord       Date:  2014-11-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.